Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
ARYA Sciences Acquisition III (ARYA)
Upcoming IPO
Vistas Media Acquisition (VMACU)
Hitek Global (HKIT)
Presidio Property Trust (SQFT)
PainReform (PRFX)
PaxMedica (PXMD)
NETSTREIT Corp. (NTST)
Duck Creek Technologies, Inc. (DCT)
Priced IPO
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
Rackspace Technology, Inc. (RXT)
BigCommerce Holdings, Inc (BIGC)
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
More companies

Vaxcyte, Inc. (PCVX)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. Their cell-free protein synthesis platform enables them to design and produce protein carriers and antigens, the critical building blocks of vaccines, in ways that they believe conventional vaccine technologies currently cannot. Their pipeline includes pneumococcal conjugate vaccine, or PCV, candidates that they believe are the most broad-spectrum PCV candidates currently in development, targeting the $7 billion global pneumococcal vaccine market. Their lead vaccine candidate, VAX-24, is a 24-valent investigational PCV that they expect to advance into clinical trials in the second half of 2021. Their cell-free protein synthesis platform, which is comprised of the XpressCF platform exclusively licensed from Sutro Biopharma, and their proprietary know-how, offers several advantages over conventional cell-based protein expression methods, which they believe enable them to generate superior, novel, more broad-spectrum and/or more immunogenic vaccines.
Industry
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
CEO CFO
Grant E. Pickering Andrew Guggenhime
Employees Founded
43 2013

Contacts

Address: 353 Hatch Drive, Foster City, CA 94404, US

Telephone: (650) 837-0111

Web page: https://www.vaxcyte.com

IPO information

Expected Date 6/12/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $794.9
Revenues (MM) $0
Net Income (Loss) (MM) $-637

Voting

What do you think will happen with the PCVX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 14
Shares Revised (MM) 15.63
Expected offer amount (MM) $250
Realized offer amount(MM) $250
Underwriters
BofA Securities/ Jefferies/ Evercore ISI
CO-Managers
Cantor/ Needham & Company

Sector: Healthcare

Tweets about $PCVX

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats